FindTrial
Sign In

Human Papillomavirus Genotyping is a Reliable Prognostic Marker of Recurrence for High-Grade Cervical Intraepithelial Neoplasia (CIN2-3) with Positive Margins after Loop Electrosurgical Excision Procedure

Human Papillomavirus Genotyping is a Reliable Prognostic Marker of Recurrence for High-Grade Cervical Intraepithelial Neoplasia (CIN2-3) with Positive Margins after Loop Electrosurgical Excision Procedure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005593
Enrollment
181
Registered
2020-11-12
Start date
2020-10-13
Completion date
Unknown
Last updated
2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Chonnam National University Hospital Hwasun Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) pathologically confirmed CIN2-3 by a LEEP; (2) patients with both pre- and post-LEEP HR HPV test results from the hybrid capture II assay (HC2) (Digene Co, Gaithersburg, MD) and the HDC test; and (3) women who received follow-up examinations for = 5 years.

Exclusion criteria

Exclusion criteria: patients with a residual CIN2-3 lesion that was confirmed within three months following the LEEP.

Design outcomes

Primary

MeasureTime frame
HPV test—

Secondary

MeasureTime frame
cytology—

Countries

Korea, Republic of

Contacts

Public ContactWOO DAE KANG

Chonnam National University Hospital Hwasun Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026